2. Search Result
Search Result
Results for "

RRMs

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Peptides

2

Inhibitory Antibodies

2

Natural
Products

1

Isotope-Labeled Compounds

9

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0527
    Pentagalloylglucose
    10+ Cited Publications

    Penta-O-galloyl-β-D-glucose; 1,2,3,4,6-Pentagalloyl glucose

    		 JAK Keap1-Nrf2 Apoptosis β-catenin Reactive Oxygen Species (ROS) E1/E2/E3 Enzyme Neurological Disease Inflammation/Immunology Cancer
    Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .
    Pentagalloylglucose
  • HY-30272
    Monobenzone
    1 Publications Verification

    		 Hapten Cancer
    Monobenzone is a potent skin depigmenting agent. Monobenzone induces depigmentation and exhibits good potential for vitiligo research. Monobenzone is a potent inhibitor of RNR (Ribonucleotide reductase) enzyme activity by targeting RRM2 (a regulatory small subunit M2 of RNR) protein, and thus has significant anti-leukemia efficacy in vitro and in vivo. Monobenzone inhibits acute myeloid leukemia (AML) cells proliferation and DNA synthesis, induces cell cycle arrest, and Apoptosis .
    Monobenzone
  • HY-P0109A
    Z-FA-FMK
    5+ Cited Publications

    (1S)-Z-FA-FMK

    		 SARS-CoV Cathepsin Apoptosis Caspase Infection Cancer
    Z-FA-FMK ((1S)-Z-FA-FMK) is a potent Cathepsin B and L inhibitor. Z-FA-FMK blocks the induction of DEVDase activity, DNA fragmentation, and externalization of phosphatidylserine by selective synthetic retinoid-related molecules (RRMs). Z-FA-FMK inhibits apoptosis. Z-FA-FMK inhibits caspase activity and selectively inhibits recombinant effector caspases 2, -3, -6, and -7. Z-FA-FMK is a viral inhibitor. Z-FA-FMK inhibits reovirus replication in a susceptible host .
    Z-FA-FMK
  • HY-108831A
    Natalizumab (Anti-CD49d)
    3 Publications Verification

    AN100226; BG00002

    		 Integrin Inflammation/Immunology Cancer
    Natalizumab (Anti-CD49d) (AN100226; BG00002) Solution is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d), blocking the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab solution inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thereby exerting anti-inflammatory and immunomodulatory activity. Natalizumab (Anti-CD49d) solution is used in the study of relapsing-remitting multiple sclerosis (RRMS) and is also applied in the research of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab (Anti-CD49d) can also prevent lymphocytes from entering the central nervous system, thus preventing acute demyelinating relapses .
    Natalizumab (Anti-CD49d)
  • HY-B2116
    Osalmid
    2 Publications Verification

    Oxaphenamide; 4'-Hydroxysalicylanilide

    		 Environmental Pollutants HBV Infection Cancer
    Osalmid is a ribonucleotide reductase small subunit M2 (RRM2) targeting compound; suppresses ribonucleotide reductase activity with an IC50 of 8.23 μM.
    Osalmid
  • HY-13010
    Laquinimod
    2 Publications Verification

    ABR-215062

    		 NF-κB Apoptosis Inflammation/Immunology
    Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .
    Laquinimod
  • HY-112358
    GW8510

    		CDK Neurological Disease Cancer
    GW8510 is a potent cyclin-dependent kinase-2 (CDK2) inhibitor. GW8510 is also a ribonucleotide reductase M2 (RRM2) inhibitor. GW8510 exhibits neuroprotective and anticancer activities .
    GW8510
  • HY-108831
    Natalizumab
    3 Publications Verification

    		 Integrin Inflammation/Immunology Cancer
    Natalizumab (AN100226; BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets α4 integrin (CD49d). It blocks the interaction of integrins such as α4β1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the α4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4 + T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohn's disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses .
    Natalizumab
  • HY-153898
    rTRD01

    		Amyloid-β Neurological Disease
    rTRD01 is an orally active, specific TDP-43 binder that targets the RRM1 and RRM2 domains of TDP-43. rTRD01 partially disrupts the interaction between TDP-43 and c9orf72 repeat RNA, but does not affect the binding of TDP-43 to canonical binding sequences. rTRD01 exhibits significant neuroprotective effects in zebrafish models, improves motor function and protects against paraquat (a widely used herbicide)-induced neurodegeneration, with no teratogenicity at high concentrations. rTRD01 is not a general antioxidant and cannot counteract Rotenone (HY-B1756)-induced neuronal death. rTRD01 can be used to study amyotrophic lateral sclerosis and other TDP-43 proteinopathies .
    rTRD01
  • HY-153736
    NSC 194308

    		DNA/RNA Synthesis Cancer
    NSC 194308, a U2AF2-RNA complexes enhancer, increases association of the U2AF1-U2AF2-SF1-splice site RNA complex by binding a site between the U2AF2 RNA recognition motifs (RRM1 and RRM2). NSC 194308 inhibits pre-mRNA splicing by stalling spliceosome assembly at the point where U2AF helps recruit U2 snRNP to the branchpoint. NSC 194308 enhances the binding of pre-mRNA to U2AF2, selectively triggering cell death in leukemia cell lines containing spliceosome mutations .
    NSC 194308
  • HY-RS12286
    RRM2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    RRM2 Human Pre-designed siRNA Set A contains three designed siRNAs for RRM2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RRM2 Human Pre-designed siRNA Set A
    RRM2 Human Pre-designed siRNA Set A
  • HY-N0527R
    Pentagalloylglucose (Standard)

    Penta-O-galloyl-β-D-glucose (Standard); 1,2,3,4,6-Pentagalloyl glucose (Standard)

    		 Reference Standards JAK Keap1-Nrf2 Apoptosis β-catenin Reactive Oxygen Species (ROS) Neurological Disease Inflammation/Immunology Cancer
    Pentagalloylglucose (Standard) is the analytical standard of Pentagalloylglucose. This product is intended for research and analytical applications. Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .
    Pentagalloylglucose (Standard)
  • HY-181846
    nTRD22

    		DNA/RNA Synthesis Neurological Disease
    nTRD22 is an RNA-binding allosteric modulator targeting TDP-43. nTRD22 binds to the N-terminal domain of TDP-43, thereby allosterically regulating the RNA-binding domain of TDP-43 and reducing its RNA-binding ability. nTRD22 decreases the TDP-43 protein level in primary motor neurons. nTRD22 alleviates motor dysfunction in amyotrophic lateral sclerosis models. nTRD22 is applicable to related research on amyotrophic lateral sclerosis .
    nTRD22
  • HY-RS12285
    RRM1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    RRM1 Human Pre-designed siRNA Set A contains three designed siRNAs for RRM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RRM1 Human Pre-designed siRNA Set A
    RRM1 Human Pre-designed siRNA Set A
  • HY-RS23051
    Rrm2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Rrm2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Rrm2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Rrm2 Rat Pre-designed siRNA Set A
    Rrm2 Rat Pre-designed siRNA Set A
  • HY-RS12287
    RRM2B Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    RRM2B Human Pre-designed siRNA Set A contains three designed siRNAs for RRM2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RRM2B Human Pre-designed siRNA Set A
    RRM2B Human Pre-designed siRNA Set A
  • HY-RS21746
    Rrm2b Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Rrm2b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rrm2b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Rrm2b Mouse Pre-designed siRNA Set A
    Rrm2b Mouse Pre-designed siRNA Set A
  • HY-W062904
    Laquinimod sodium

    ABR-215062 sodium

    		 NF-κB Apoptosis Neurological Disease Inflammation/Immunology
    Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .
    Laquinimod sodium
  • HY-13010S
    Laquinimod-d5

    ABR-215062-d5

    		 Isotope-Labeled Compounds Apoptosis NF-κB Inflammation/Immunology
    Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .
    Laquinimod-d5
  • HY-13010R
    Laquinimod (Standard)

    ABR-215062 (Standard)

    		 Reference Standards NF-κB Apoptosis Inflammation/Immunology
    Laquinimod (Standard) is the analytical standard of Laquinimod. This product is intended for research and analytical applications. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .
    Laquinimod (Standard)
  • HY-RS25122
    Rrm1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Rrm1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Rrm1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Rrm1 Rat Pre-designed siRNA Set A
    Rrm1 Rat Pre-designed siRNA Set A
  • HY-RS16616
    Rrm2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Rrm2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rrm2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Rrm2 Mouse Pre-designed siRNA Set A
    Rrm2 Mouse Pre-designed siRNA Set A
  • HY-RS18637
    Rrm1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Rrm1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rrm1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Rrm1 Mouse Pre-designed siRNA Set A
    Rrm1 Mouse Pre-designed siRNA Set A
  • HY-RS28263
    Rrm2b Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Rrm2b Rat Pre-designed siRNA Set A contains three designed siRNAs for Rrm2b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Rrm2b Rat Pre-designed siRNA Set A
    Rrm2b Rat Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: